Understand the source comparison
Best Peptides for Interstitial Cystitis: Research Comparison
Before evaluating specific peptide compounds, understand that no peptide has FDA approval for interstitial cystitis treatment. The table below compares investigational peptides based on preclinical research mechanisms, not clinical efficacy data. BPC-157 VEGF/
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before evaluating specific peptide compounds, understand that no peptide has FDA approval for interstitial cystitis treatment. The table below compares investigational peptides based on preclinical research mechanisms, not clinical efficacy data.
- BPC-157
- VEGF/FGF upregulation for mucosal angiogenesis and collagen synthesis
- Rodent bladder fistula models show 40% faster closure vs controls (J Physiol Pharmacol 2019)
- Intraperitoneal, oral (gastric stability reported)
- Rapid urinary degradation; intravesical delivery untested in controlled trials
- Strongest preclinical evidence for tissue repair but lacks human bladder-specific trials
- Thymosin Beta-4
- Macrophage M1→M2 polarisation; reduces TNF-α, IL-1β secretion
- Chemically induced cystitis models demonstrate 55% reduction in inflammation scores (U Michigan)
- Subcutaneous, intraperitoneal
- Requires modified formulation for bladder retention
- Immunomodulatory mechanism addresses chronic inflammation; human dry eye trials show safety profile
- KPV (tripeptide)
- NF-κB nuclear translocation inhibitor; blocks inflammatory gene transcription
- Colitis models (60–70% inflammatory marker reduction); bladder applications extrapolated from gut research
- Oral, subcutaneous, rectal (colitis studies)
- Poor systemic bioavailability; intravesical concentration-time data unavailable
- Mechanistically relevant but lacks IC-specific preclinical models; mostly a research tool compound
- LL-37 (cathelicidin)
- Antimicrobial peptide with immune modulation; proposed for bacterial cystitis co-factors
- In vitro bladder cell culture studies; no in vivo IC models published
- Intravesical instillation (theoretical)
- Enzymatic degradation in urine; cytotoxicity at high concentrations
- Interesting for infection-triggered IC subtypes but very early-stage research